36
Participants
Start Date
April 4, 2020
Primary Completion Date
July 3, 2024
Study Completion Date
June 30, 2025
Tildrakizumab
"Tildrakizumab, a p19 inhibitor which blocks IL-23 and Th17 mediated inflammation, will be given for 6 months. As below, a baseline cardiac PET scan will be performed prior to initiation and after 6 months of treatment.~Radiation: A cardiac PET scan will be performed at baseline and at 6 months"
Brigham and Women's Hospital, Boston
Marcelo F. Di Carli, MD, FACC
OTHER